Psilocybin, the psychoactive compound found in magic mushrooms, is as effective at treating depression as conventional SSRI antidepressants. Researchers report, that although not significantly significant, early findings reveal those treated with psilocybin experienced more rapid and greater reductions in depression symptoms than those treated with SSRIs.
While England has only seen a moderate rise in people being diagnosed with psychosis in recent years, prescription rates for antipsychotic medications have doubled.
Activity of the c-Fos gene begins the increase on the ninth day of exposure to antidepressants. By day 14, mice showed behavioral changes associated with SSRI use. This may explain why suicide rates drop after nine days of treatment, and symptoms of depression improve after three weeks.
A new study reveals some drug combinations may be more beneficial for those with schizophrenia. Researchers found people with schizophrenia who took antidepressants, in combination with other medications, were less likely to be hospitalized for mental health issues than those who started another antipsychotic.
Researchers report, contrary to popular belief, Adderall and other ADHD drugs do not improve cognition in healthy college students. Instead, they may impair cognitive function.
A new study reveals a psychostimulant prescribed for ADHD increases glutamate in the brains of healthy people, resulting in more positive emotions.
A new study reports the way antidepressants affect learning about control and helplessness could explain why the therapeutic effects take time, as well as why their effectiveness differs among people.
A new study shows the effectiveness of ketamine in treating depression in a mouse model of the disease and also helps bring together two hypotheses for the cause of depression.
Researchers report the antidepressant paroxetine suppresses neuroinflammation in improves reaction time in people with HIV associated cognitive impairment.